Results 101 to 110 of about 510 (116)
Drugs of the Future, 2000 Some of the next articles are maybe not open access.
Related searches:
Related searches:
Evaluation of Intraocular Pharmacokinetics and Toxicity of Prinomastat (AG3340) in the Rabbit
Journal of Ocular Pharmacology and Therapeutics, 2001To determine the ocular pharmacokinetics, physiological and histological effects of prinomastat (a matrix metalloprotease inhibitor), a total of seventy-seven eyes of New Zealand White rabbits received intravitreous and subtenon injections of prinomastat or of acidified water vehicle as control, Doses of 0.5 mg in 0.05 mL of prinomastat or acidified ...
Lingyun Cheng +2 more
exaly +3 more sources
Current Eye Research, 2000
To determine the efficacy of prinomastat (AG3340), a synthetic inhibitor of matrix metalloproteinase, in the treatment of experimental proliferative vitreoretinopathy (PVR) induced by intravitreal dispase injection.One eye each of 53 New Zealand white rabbits was injected in the vitreous cavity with 0.07 unit of dispase to induce PVR.
William Freeman +2 more
exaly +5 more sources
To determine the efficacy of prinomastat (AG3340), a synthetic inhibitor of matrix metalloproteinase, in the treatment of experimental proliferative vitreoretinopathy (PVR) induced by intravitreal dispase injection.One eye each of 53 New Zealand white rabbits was injected in the vitreous cavity with 0.07 unit of dispase to induce PVR.
William Freeman +2 more
exaly +5 more sources
Current Eye Research, 2002
To study the activity of the novel anti-angiogenic compound AG3340 (Prinomastat), a selective inhibitor of matrix metalloproteases, in an animal model of retinal neovascularization.C57BL/6J mice were used to produce oxygen-induced retinal neovascularization.
William Freeman +2 more
exaly +3 more sources
To study the activity of the novel anti-angiogenic compound AG3340 (Prinomastat), a selective inhibitor of matrix metalloproteases, in an animal model of retinal neovascularization.C57BL/6J mice were used to produce oxygen-induced retinal neovascularization.
William Freeman +2 more
exaly +3 more sources
Lung Cancer, 2003
We studied the synthetic matrix metalloproteinase inhibitor (MMPI) prinomastat (AG3340) in a well-established NCI-H460 orthotopic lung cancer model that exhibits highly predictable regional and systemic metastatic patterns. Both primary and metastatic tumors express the matrix metalloproteinases (MMP-2), MT1-MMP (MMP-14) and tissue inhibitor of ...
Ming-Sound Tsao, Michael R Johnston
exaly +3 more sources
We studied the synthetic matrix metalloproteinase inhibitor (MMPI) prinomastat (AG3340) in a well-established NCI-H460 orthotopic lung cancer model that exhibits highly predictable regional and systemic metastatic patterns. Both primary and metastatic tumors express the matrix metalloproteinases (MMP-2), MT1-MMP (MMP-14) and tissue inhibitor of ...
Ming-Sound Tsao, Michael R Johnston
exaly +3 more sources
Thrombosis and Haemostasis, 2003
SummaryTwo clinical trials have suggested that the combination of vascular endothelial growth factor inhibitor with chemotherapy is associated with venous thromboembolism (VTE). This retrospective cohort study investigates whether a similar association exists when matrix metalloproteinase inhibitor (prinomastat) is combined with chemotherapy.Patients ...
Carolyn E, Behrendt, Rolando B, Ruiz
exaly +3 more sources
SummaryTwo clinical trials have suggested that the combination of vascular endothelial growth factor inhibitor with chemotherapy is associated with venous thromboembolism (VTE). This retrospective cohort study investigates whether a similar association exists when matrix metalloproteinase inhibitor (prinomastat) is combined with chemotherapy.Patients ...
Carolyn E, Behrendt, Rolando B, Ruiz
exaly +3 more sources
Expert Opinion on Investigational Drugs, 2000
Prinomastat (formerly AG3340, Agouron Pharmaceuticals, Inc.) is a potent, selective oral inhibitor of matrix metalloproteinase-2, -9, -13 and -14. This peculiar selectivity should represent an advantage for prinomastat in terms of efficacy/tolerability. The drug has been shown to inhibit tumour growth and angiogenesis in a variety of preclinical models,
Roberto Scatena
exaly +3 more sources
Prinomastat (formerly AG3340, Agouron Pharmaceuticals, Inc.) is a potent, selective oral inhibitor of matrix metalloproteinase-2, -9, -13 and -14. This peculiar selectivity should represent an advantage for prinomastat in terms of efficacy/tolerability. The drug has been shown to inhibit tumour growth and angiogenesis in a variety of preclinical models,
Roberto Scatena
exaly +3 more sources
Prinomastat MMPI Disappointing for Advanced Prostate Cancer
Oncology Times, 2001exaly +2 more sources
Cancer Research, 2004
Abstract Photodynamic therapy (PDT) clinical results are promising; however, tumor recurrences can occur and, therefore, methods for improving treatment efficacy are needed. PDT elicits direct tumor cell death and microvascular injury as well as expression of angiogenic, inflammatory, and prosurvival molecules.
Angela, Ferrario +8 more
openaire +2 more sources
Abstract Photodynamic therapy (PDT) clinical results are promising; however, tumor recurrences can occur and, therefore, methods for improving treatment efficacy are needed. PDT elicits direct tumor cell death and microvascular injury as well as expression of angiogenic, inflammatory, and prosurvival molecules.
Angela, Ferrario +8 more
openaire +2 more sources